

Precision flow cytometry delivering deeper immune insights

Advance your therapeutic pipeline with high-quality conventional and spectral flow cytometry expertise designed for the complexity of today's drug development. Whether you are working on hematological malignancies, cell therapy, or biomarker discovery, our team provides the scientific rigor and flexibility needed to keep your programs moving forward with confidence.

Access a full range of validated off-the-shelf assays and customized services spanning exploratory panels through clinically validated LDTs supporting primary and secondary endpoints.

Validated off-the-shelf assays

MRD		
Sample type: bone marrow, peripheral blood		
Assay	Markers	Cell type
B-ALL MRD panel	CD3, CD9, CD10, CD13, CD19, CD20, CD33, CD34, CD38, CD45, CD58, CD71, Syto16, 7-AAD	Lymphocytes, CD45 dim, detection of residual B-lymphoblasts
CLL MRD modified ERIC panel	7-AAD, CD5, CD19, CD20, CD43, CD45, CD79b, CD81, ROR1	Lymphocytes, detection of residual CLL cells
Multiple myeloma MRD panel	CD19, CD20, CD27, CD38, CD45, CD56, CD81, CD117, CD138, cKappa, cLambda	Lymphocytes, normal/abnormal plasma cells, intra cellular light chain restriction evaluation, detection of residual malignant plasma cells

Immunophenotyping		
Sample type: peripheral blood mononuclear cells		
Assay	Markers	Cell type
MDSC/DC panel	CD1c, CD3, CD11b, CD11c, CD14, CD15, CD16, CD19, CD33, CD56, CD123, CD141, HLA-DR	MDSC subsets, monocytes, B-cell, NK-cell, T-cell, antigen presentation, dendritic cell subsets
Activation and phenotyping panel	CD3, CD4, CD8, CD16, CD45, CD56, CD152 (CTLA-4), CD223 (LAG-3), CD274 (PD-L1), CD279 (PD-1), CD366 (TIM-3), TIGIT	Lymphocytes, T-cell, B-cell, monocytes, NK-cell, T-cell immune checkpoint
BD TBNK™ Panel	CD3, CD4, CD8, CD16, CD19, CD45, CD56	Lymphocytes, T-cell, B-cell, NK-cell
Sample type: peripheral blood		
Assay	Markers	Cell type
BD Multitest™ 6-color TBNK panel with Trucount tubes	CD3, CD4, CD8, CD16, CD19, CD45, CD56	Lymphocytes, T-cell, B-cell, NK-cell, cell enumeration
Adaptive NK-cell subset panel	CD3, CD16, CD38, CD56, CD57, CD94, CD107a (LAMP-1), CD158 (KIR2DL1), CD159a (NKG2A), CD159c (NKG2C), CD314 (NKG2D), CD335 (NKp46), CD337 (NKp30), Granzyme B, HLA-DR, Ki-67	Antigen presentation, cytotoxicity, monocytes, neutrophils, macrophages, NK-cell, NKT, NK-cell activation, proliferation

Comprehensive T-cell and monocyte panel	CD3, CD4, CD8, CD14, CD19, CD25, CD27, CD28, CD45, CD45RA, CD57, CD127, CD197 (CCR7), Ki-67, TCR V λ 9, TCR V δ 2	Lymphocytes, monocytes, B-cell, B-cell memory, NK-cell, T-cell, $\lambda\delta$ T-cell subsets, T-cell activation, T-cell costimulation, T-cell memory, Treg, proliferation
Cytek® cFLUOR immunoprofiling kit	CD3, CD4, CD8, CD14, CD16, CD19, CD25, CD27, CD45, CD45RA, CD56, CD127, CD197 (CCR7), IgD	Lymphocytes, monocyte subsets, neutrophils, macrophages, B-cell, B-cell memory, B-cell class switching, NK-cell subsets, T-cell, T-cell activation, T-cell costimulation, T-cell memory, Treg
Flow Cast® Basophil activation test (BAT)	CCR3, CD63, CD203c	Activated basophils (fMLP and FceR1)
MDSC and dendritic cell panel	CD3, CD11b, CD11c, CD14, CD15, CD19, CD33, CD56, CD123, CD141, HLA-DR	MDSC subsets, monocytes, B-cell, NK-cell, T-cell, antigen presentation, dendritic cell subsets
NK cell subset Panel	CD3, CD16, CD38, CD56, CD57, CD94, CD107a, CD158, CD159a, CD314, CD335, CD337, HLA-DR, Granzyme B, Ki-67	Antigen presentation, cytotoxicity, monocytes, macrophages, NK-cell, NKT, NK-cell subsets and activation, proliferation
T-cell gamma delta panel	CD3, CD4, CD8, CD27, CD45, CD314 (NKG2D), CD335 (NKp46), CD337 (NKp30), Ki-67, TCR V γ 9, TCR V δ 2	Lymphocytes, NK-cell subsets and activation, T-cell, $\lambda\delta$ T-cell subsets, $\lambda\delta$ T-cell costimulation, T-cell costimulation, Treg, proliferation
T-cell subset panel	CD3, CD4, CD8, CD19, CD25, CD27, CD28, CD45, CD45RA, CD57, CD127, CD197 (CCR7), Ki-67	Lymphocytes, B-cell, B-cell memory, NK-cell, T-cell, T-cell activation, T-cell costimulation, T-cell memory, Treg, proliferation
TBNK dendritic activation panel 2	CD3, CD4, CD8, CD11c, CD19, CD45RA, CD56, CD69, CD86, CD197, Granzyme B, HLA-DR, Ki-67	Lymphocytes, dendritic cells, antigen presentation, B-cell, NK-cell, T-cell, T-cell activation, T-cell memory, cytotoxicity, proliferation: Ki-67
T-cell activation and exhaustion panel	CD3, CD4, CD8, CD25, CD45RA, CD69, CD127, CD197 (CCR7), CD223 (LAG-3), CD279 (PD-1), CD366 (TIM-3), Granzyme B, Ki-67, viability	T-cell, T-cell activation, T-cell memory, Treg, T-cell Immune checkpoint, cytotoxicity, proliferation, viability
T-cell and NK-cell subset activation panel	CD3, CD4, CD8, CD16, CD25, CD45, CD45RA, CD56, CD137 (4-1BB), CD152 (CTLA-4), CD197 (CCR7), CD223 (LAG-3), CD279 (PD-1), FOXP3, Ki-67, TIGIT	Macrophages, NK-cell subsets, NKT, T-cell, T-cell activation, T-cell memory, Treg, T-cell immune checkpoint, cytotoxicity, proliferation
T-cell subset and monocyte function panel	CD3, CD4, CD8, CD14, CD19, CD25, CD27, CD28, CD45, CD45RA, CD57, CD127, CD197 (CCR7), Ki-67	Lymphocytes, monocytes, B-cell, B-cell memory, NK-cell, T-cell, T-cell activation, T-cell costimulation, T-cell memory, Treg, proliferation
T-cell profiling assay	CD3, CD4, CD8, CD25, CD45RA, CD137 (4-1BB), CD197 (CCR7), CD223 (LAG-3), CD274 (PD-L1), CD279 (PD-1), FOXP3, Ki-67, TIGIT	Lymphocytes, T-cell, T-cell activation, T-cell malignancy, T-cell memory, Treg, T-cell immune checkpoint, proliferation
Sample type: bone marrow		
Assay	Markers	Cell type
MDSC-dendritic cell assay	CD1c, CD3, CD11b, CD11c, CD14, CD15, CD16, CD19, CD33, CD56, CD123, CD141, CD163, HLA-DR	MDSC subsets, monocyte and macrophage subsets, neutrophils, B-cell, NK-cell, T-cell, antigen presentation, dendritic cell subsets

T-cell and NK-cell profiling assay	CD3, CD4, CD7, CD8, CD11b, CD14, CD16, CD19, CD25, CD45, CD45RA, CD56, CD137 (4-1BB), CD197 (CCR7), CD223 (LAG-3), CD274 (PD-L1), CD279 (PD-1), CD314 (NKG2D), CD335 (NKp46), CD337 (NKp30), FOXP3, Ki-67, TIGIT	Lymphocytes, monocyte subsets, macrophages, NK-cell subsets and activation, NKT, B-cell, T-cell, T-cell activation, T-cell malignancy, T-cell memory, Treg, T-cell immune checkpoint, proliferation
---	--	---

Sample type: peripheral blood, bone marrow

Assay	Markers	Cell type
Expanded MDSC and dendritic cell panel	CD1c, CD3, CD11b, CD11c, CD14, CD15, CD16, CD19, CD33, CD56, CD123, CD141, CD163, HLA-DR	MDSC subsets, monocyte and macrophage subsets, neutrophils, B-cell, NK-cell, T-cell, antigen presentation, dendritic cell subsets

Malignant Neoplasms

Sample type: bone marrow, peripheral blood

Assay	Markers	Cell type
AML follow-up panel	7AAD, CD11b, CD13, CD14, CD16, CD19, CD33, CD34, CD45, CD64, CD117, CD123, HLA-DR, cMPO, nTDT, cCD3, cCD22, cCD79a	Lymphocytes, CD45 dim (detection of myeloblasts), monocytes, granulocytes, assessment of myeloid malignancy
B-ALL add-on panel	CD10, CD19, CD34, CD45, cCD3, cCD22, cCD79a, nTDT, cMPO	Lymphocytes, CD45 dim (detection/confirmation of lymphoblasts), granulocytes, assessment of B-cell lymphoid malignancy
B-cell lymphoma follow-up panel	7AAD, CD5, CD10, CD11c, CD19, CD20, CD23, CD45, FMC7, Lambda, Kappa	Lymphocytes, assessment of B-cell lymphoid malignancy, distinguishes CLL and MCL, light chain restriction evaluation
BCMA multiple myeloma panel	CD19, CD38, CD45, CD56, CD138, CD269 (BCMA), cLambda, cKappa	Normal/abnormal plasma cells, monitoring BCMA, intracellular light chain restriction evaluation
CLL/mantle cell lymphoma panel	7AAD, CD3, CD5, CD19, CD22, CD36, CD43, CD45, CD52, CD200	Lymphocytes, differentiation between CLL and MCL
Extended leukemia/lymphoma panel	7AAD, CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD11b, CD11c, CD13, CD14, CD15, CD16, CD19, CD20, CD23, CD33, CD34, CD38, CD41, CD45, CD56, CD64, CD71, CD117, CD138, FMC7, Glyco A, HLA-DR, Kappa, Lambda	Lymphocytes, B-cell, T-cell, NK-cell/NKT-cell, CD45 dim (detection of blasts), hematogones, granulocytes, monocytes, plasma cells, identification of M6/M7 subtypes of AML, light chain restriction evaluation
Plasma cell panel	7AAD, CD19, CD20, CD38, CD45, CD56, CD117, CD138, cKappa, cLambda	Lymphocytes, normal/ abnormal plasma cells, intracellular light chain restriction evaluation
Standard leukemia/lymphoma panel	7AAD, CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD11c, CD13, CD14, CD16, CD19, CD20, CD23, CD33, CD34, CD38, CD45, CD56, CD64, CD117, HLA-DR, Kappa, Lambda	Lymphocytes, B-cell, T-cell, NK-cell/NKT-cell, CD45 dim (detection of blasts), hematogones, granulocytes, monocytes, plasma cells, light chain restriction evaluation
T-ALL add-on panel	7AAD, CD1a, CD7, CD11b, CD19, CD43, CD45, cCD3, cMPO, nTDT	Lymphocytes, CD45 dim, identification of T-lymphoblasts

Sample type: peripheral blood

Assay	Markers	Cell type
T-cell & B-cell panel	7AAD, CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD11c, CD19, CD20, CD23, CD34, CD38, CD45, CD56, Kappa, Lambda	Lymphocytes, B-cell, T-cell, NK-cell/ NKT-cell, CD45 dim, plasma cells, light chain restriction evaluation
T-cell therapy panel	7AAD, CD3, CD4, CD7, CD8, CD25, CD26, CD30, CD45, CD52, CD279	Lymphocytes, T-cell, identification of Sézary Syndrome, identification of Anaplastic large cell lymphoma, T-cell activation, T-cell immune checkpoint

Non-Malignant Neoplasms

Sample type: peripheral blood

Assay	Markers	Cell type
PNH panel	CD14, CD15, CD24, CD45, CD59, CD64, CD235a, FLAER	Red blood cells, granulocytes, monocytes, detection of PNH clones

BM: bone marrow, PB: peripheral blood, PBMC: peripheral blood mononuclear cells, MRD: molecular residual disease, ERIC: European Research Initiative of Chronic Lymphocytic Leukemia

Availability is subject to change. For a current listing, please contact a NeoGenomics representative.

To learn more about **NeoGenomics Pharma Services**, visit us online at [NeoGenomics.com/Partners](https://www.NeoGenomics.com/Partners), call us at 866.776.5907, option 3, or email us at ContactPharma@NeoGenomics.com.

NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and oncology data solutions. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and a CAP-accredited full-service, sample-processing laboratory in Cambridge, England, United Kingdom. ©2026 NeoGenomics Laboratories, Inc. All rights reserved.



9490 NeoGenomics Way
Fort Myers, FL 33912
Phn: 866.776.5907
Fax: 239.690.4237

[NeoGenomics.com](https://www.NeoGenomics.com)
All trademarks are the property of their respective owners.
CORP-MRKT-0392 03.26